Tofacitinib Citrate (CP-690550 citrate): Selective JAK3 Inhibitor for Immune Regulation Research

Executive Summary: Tofacitinib citrate (CP-690550 citrate) is a highly potent and selective inhibitor of Janus kinase 3 (JAK3), with an IC₅₀ of ~1 nM for JAK3 and at least 20-fold lower potency toward JAK2 and JAK1 [APExBIO]. It suppresses lymphocyte proliferation and modulates Th1/Th2/Th17 and regulatory T cell differentiation by interfering with cytokine-induced signaling. In human endothelial inflammation models, tofacitinib reduces intercellular adhesion molecule 1 (ICAM-1) and E-selectin induction at 1 μM, but can enhance VCAM-1 and ICAM-1 expression at 10 μM (Zavoriti & Miossec 2025). The compound is soluble at ≥25.22 mg/mL in DMSO and ≥3.4 mg/mL in water with warming. It is widely used for JAK-STAT pathway studies, immune modulation, and modeling inflammatory or autoimmune diseases.

Biological Rationale

Janus kinases (JAKs) are non-receptor tyrosine kinases that mediate the signaling of various cytokines involved in hematopoiesis and immune regulation. JAK3 is mainly expressed in hematopoietic cells, where it partners with the common gamma chain (γc) subunit of multiple interleukin receptors (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21). Dysregulation of the JAK-STAT pathway contributes to autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (Zavoriti & Miossec 2025). Inhibition of JAK3 selectively disrupts lymphocyte proliferation, survival, and differentiation, enabling researchers to dissect immune responses and model pathologies driven by aberrant cytokine signaling.

Mechanism of Action of Tofacitinib citrate (CP-690550 citrate)

Tofacitinib citrate is a small-molecule inhibitor developed to target JAK3 with high potency and selectivity. The compound binds to the ATP-binding site of JAK3, inhibiting its kinase activity. In vitro, tofacitinib exhibits an IC₅₀ of approximately 1 nM against JAK3, compared to 20-fold and 100-fold weaker inhibition of JAK2 and JAK1, respectively (APExBIO). Reported equilibrium dissociation constants (K_i) are 6.5 nM for JAK3, 21.7 nM for JAK2, and 1.6 nM for JAK1. This selectivity profile allows targeted modulation of γc-cytokine signaling pathways while minimizing off-target effects on other JAK isoforms. In cellular models, tofacitinib suppresses IFN-γ and IL-4 production under Th1 and Th2 differentiation conditions, respectively, and modulates IL-17, Foxp3, and IL-10 expression during Th17 polarization.

Evidence & Benchmarks

• Tofacitinib citrate inhibits JAK3 with an IC₅₀ of ~1 nM, while inhibition of JAK2 and JAK1 is 20-fold and 100-fold less potent, respectively (APExBIO).
• Binding affinity studies report K_i values of 6.5 nM (JAK3), 21.7 nM (JAK2), and 1.6 nM (JAK1) under standard kinase assay conditions (APExBIO).
• At 1 μM, tofacitinib reduces ICAM-1 and E-selectin upregulation in TNF+IL-17A-stimulated human endothelial cells; however, at 10 μM, it increases VCAM-1 and ICAM-1 induction (Zavoriti & Miossec 2025).
• JAK inhibition with tofacitinib suppresses IL-6 release in inflamed endothelial cells, consistent with disruption of cytokine-driven proinflammatory signaling (Zavoriti & Miossec 2025).
• Tofacitinib is used at concentrations ranging from 10 nM to 100 nM in typical cell-based assays, according to the cell type and experimental setup (APExBIO).

Applications, Limits & Misconceptions

Tofacitinib citrate is widely utilized in immune regulation research, autoimmune disease modeling, and dissection of JAK-STAT pathway signaling. It enables precise modulation of lymphocyte activation, differentiation, and cytokine production in vitro and in vivo. Its selectivity for JAK3 makes it ideal for studies targeting γc-cytokine-dependent processes without broadly inhibiting all JAK isoforms. Notably, in endothelial models of inflammation, tofacitinib suppresses key adhesion molecules at lower concentrations but may paradoxically enhance pro-thrombotic markers at higher doses, underscoring the necessity for dose optimization (Zavoriti & Miossec 2025).

For further practical guidance, see "Tofacitinib Citrate in Immune Regulation: Workflows & Troubleshooting", which details experimental protocol optimization, while the present article updates these insights with specific cardiovascular and endothelial benchmarks. Additionally, "Navigating the Translational Frontier: Strategic Insights" explores translational aspects; here we clarify the comparative effects among JAK inhibitors based on recent endothelial studies.

Common Pitfalls or Misconceptions

• Tofacitinib does not directly block TNF or IL-17A signaling: These cytokines act independently of the JAK-STAT pathway (Zavoriti & Miossec 2025).
• High concentrations (≥10 μM) may induce paradoxical upregulation of VCAM-1 and ICAM-1: Dose titration is critical to avoid off-target effects (Zavoriti & Miossec 2025).
• Thrombomodulin downregulation is not prevented by tofacitinib: The compound does not fully protect against endothelial procoagulant shifts under inflammatory stress (Zavoriti & Miossec 2025).
• Solubility is limited in ethanol: Dissolve tofacitinib citrate in DMSO or water with ultrasonication and warming for best results (APExBIO).
• Long-term storage of DMSO solutions is discouraged: Prepare fresh aliquots for reproducibility (APExBIO).

Workflow Integration & Parameters

Tofacitinib citrate is supplied as a solid by APExBIO and should be stored at -20°C. For cell-based assays, prepare stock solutions at ≥25.22 mg/mL in DMSO or ≥3.4 mg/mL in water using gentle warming and ultrasonic treatment. The compound is insoluble in ethanol. Working concentrations typically range from 10 nM to 100 nM, though endothelial models may require up to 1 μM for functional readouts. Avoid exceeding 10 μM to minimize off-target or paradoxical effects. Stock solutions in DMSO are stable below -20°C for several months, but repeated freeze-thaw cycles or long-term storage are not recommended. Refer to the Tofacitinib citrate (CP-690550 citrate) product page for extended handling and solubility data.

Conclusion & Outlook

Tofacitinib citrate (CP-690550 citrate) remains a benchmark tool for dissecting JAK-STAT signaling and immune regulation in preclinical research. Its high potency, well-defined selectivity, and reproducible effects support its continued use for studies on lymphocyte proliferation, cytokine signaling, and inflammatory disease models. While cardiovascular safety and endothelial effects require careful dose titration, especially in translational research, the compound's robust profile makes it a key asset for mechanistic and disease modeling applications. For sourcing, APExBIO provides rigorously characterized material under SKU A4135.